|
🐜
|
131I-tositumomab therapy as initial treatment for follicular lymphoma.
11 auth.
M. Kaminski,
M. Tuck,
J. Estes,
A. Kolstad,
C. Ross,
K. Zasadny,
...
D. Regan,
P. Kison,
S. Fisher,
S. Kroll,
R. Wahl
|
9 |
2005 |
9
🐜
|
|
🐜
|
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
35 auth.
N. Fowler,
M. Dickinson,
M. Dreyling,
J. Martínez-López,
A. Kolstad,
J. Butler,
M. Ghosh,
L. Popplewell,
J. Chavez,
E. Bachy,
Koji Kato,
H. Harigae,
M. Kersten,
C. Andreadis,
P. Riedell,
...
P. Ho,
J. Pérez-Simón,
A. Chen,
L. Nastoupil,
B. von Tresckow,
A. Ferreri,
T. Teshima,
P. Patten,
J. Mcguirk,
A. Petzer,
F. Offner,
A. Viardot,
P. Zinzani,
R. Malladi,
Aiesha Zia,
R. Awasthi,
Aisha Masood,
O. Anak,
S. Schuster,
C. Thieblemont
|
8 |
2021 |
8
🐜
|
|
🐜
|
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
19 auth.
C. Eskelund,
Christina Dahl,
J. W. Hansen,
Maj Westman,
A. Kolstad,
L. Pedersen,
Carmen P. Montaño-Almendras,
S. Husby,
C. Freiburghaus,
S. Ek,
...
Anja Pedersen,
C. Niemann,
R. Räty,
P. Brown,
C. Geisler,
M. Andersen,
P. Guldberg,
M. Jerkeman,
K. Grønbæk
|
8 |
2017 |
8
🐜
|
|
🐜
|
Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur
21 auth.
C. Geisler,
A. Kolstad,
A. Laurell,
M. Jerkeman,
R. Räty,
N. Andersen,
L. Pedersen,
M. Eriksson,
M. Nordström,
E. Kimby,
...
H. Bentzen,
O. Kuittinen,
G. Lauritzsen,
H. Nilsson‐Ehle,
E. Ralfkiær,
M. Ehinger,
C. Sundström,
J. Delabie,
M. Karjalainen-Lindsberg,
P. Brown,
E. Elonen
|
8 |
2012 |
8
🐜
|
|
🐜
|
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
20 auth.
F. Morschhauser,
J. Radford,
A. van Hoof,
U. Vitolo,
P. Soubeyran,
H. Tilly,
P. Huijgens,
A. Kolstad,
F. d'Amore,
Marcos González Diaz,
...
M. Petrini,
C. Sebban,
P. Zinzani,
M. V. van Oers,
W. van Putten,
A. Bischof-Delaloye,
A. Rohatiner,
G. Salles,
J. Kuhlmann,
A. Hagenbeek
|
8 |
2008 |
8
🐜
|
|
🐜
|
15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
27 auth.
C. Eskelund,
A. Kolstad,
M. Jerkeman,
R. Räty,
A. Laurell,
S. Eloranta,
K. Smedby,
S. Husby,
L. Pedersen,
N. Andersen,
M. Eriksson,
E. Kimby,
H. Bentzen,
O. Kuittinen,
G. Lauritzsen,
...
H. Nilsson‐Ehle,
E. Ralfkiær,
M. Ehinger,
C. Sundström,
J. Delabie,
M. Karjalainen-Lindsberg,
C. Workman,
Christian Garde,
E. Elonen,
P. Brown,
K. Grønbæk,
C. Geisler
|
7 |
2016 |
7
🐜
|
|
🐜
|
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
19 auth.
C. Geisler,
A. Kolstad,
A. Laurell,
R. Räty,
M. Jerkeman,
M. Eriksson,
M. Nordström,
E. Kimby,
A. Boesen,
H. Nilsson‐Ehle,
...
O. Kuittinen,
G. Lauritzsen,
E. Ralfkiaer,
M. Ehinger,
C. Sundström,
J. Delabie,
M. Karjalainen-Lindsberg,
P. Brown,
E. Elonen
|
7 |
2010 |
7
🐜
|
|
🐜
|
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases.
27 auth.
A. Hadzidimitriou,
A. Agathangelidis,
N. Darzentas,
F. Murray,
M. Delfau-Larue,
L. Pedersen,
A. López,
Antonis Dagklis,
P. Rombout,
K. Beldjord,
A. Kolstad,
M. Dreyling,
A. Anagnostopoulos,
A. Tsaftaris,
P. Mavragani-Tsipidou,
...
A. Rosenwald,
M. Ponzoni,
P. Groenen,
P. Ghia,
B. Sander,
T. Papadaki,
E. Campo,
C. Geisler,
R. Rosenquist,
F. Davi,
C. Pott,
K. Stamatopoulos
|
7 |
2011 |
7
🐜
|
|
🐢
|
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment.
13 auth.
O. Yri,
D. Torfoss,
O. Hungnes,
A. Tierens,
K. Waalen,
T. Nordøy,
S. Dudman,
A. Kilander,
K. Wader,
B. Ostenstad,
...
R. Ekanger,
P. Meyer,
A. Kolstad
|
7 |
2011 |
7
🐢
|
|
🐢
|
The Patient Experiences Questionnaire: development, validity and reliability.
K. Pettersen,
M. Veenstra,
B. Guldvog,
A. Kolstad
|
7 |
2004 |
7
🐢
|
|
🐜
|
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
13 auth.
J. Myklebust,
J. Irish,
J. Brody,
D. Czerwinski,
R. Houot,
H. Kohrt,
J. Timmerman,
J. Said,
Michael R. Green,
J. Delabie,
...
A. Kolstad,
Ash A. Alizadeh,
R. Levy
|
7 |
2013 |
7
🐜
|
